Diagnologix pioneers the development of innovative cell-processing systems to sort, isolate, and manipulate circulating tumor cells (CTCs), stem cells , and immune cells in bulk-volume biological fluids (e.g. blood) for research and clinical applications. Currently, the main focus is on streamlining the workflows for sorting and expanding both the naive T cells and stem cells from blood to overcome clinical and cell processing bottlenecks of adoptive cell therapy (ACT) for cancer treatment and stem cell transplantation. Diagnologix experimentally discovered and creatively applied the lipid shelled perfluorocarbon-filled microbubble (MB), which has been approved by the FDA for use as an ultrasound contrast agent, as a self-driving vehicle for cell separation and as a tunable artificial cell for target-cell regulation. Our side-by-side comparisons have shown that this product outperformed the leading reagents in current market. Diagnologix accomplished this through its proprietary microbubble and device engineering. We welcome collaboration with both industry and academia to form synergistic partnerships.
Preclinical Validation: Naïve T cells were isolated by sequential sorting with 3 targeted lipid shell microbubbles (conjugated with anti-CD8, anti-CD45RA, and anti-CD62L, respectively). To generate CD19-CAR-modified Tscm-enriched cells, isolated naïve T cells were activated by anti-CD3/CD28 conjugated microbubbles and transduced by CD19-CAR retrovirus via Retronectin conjugated microbubbles. Transduced naïve T cells were cultured in media with IL-7, IL-21, and TWS119. Control CD19-CAR T cells were produced from same donors' PBMCs using standard culture conditions (soluble IL-2 and anti-CD3/CD28 coated culture flasks). Tscm-enriched and standard CD19-CAR T cells were injected into Raji-luc-bearing NSG mice. Tumor burden was measured by the Xenogen IVIS system.